ClinicalTrials.gg
Not yet recruitingNCT07733596Updated Jul 29, 2026

Development of a Digital Acceptance and Commitment Therapy Intervention for Suicide Prevention in Adults Through Co-design

An interventional study of Digital ACT Intervention in Suicide, Co-design and Suicide Prevention, sponsored by The Hong Kong Polytechnic University. Not yet recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-29.

Primary conditionSuicide PreventionRegistry: SuicideReclassifiedWhy we changed it
Registry
Suicide — the first condition term the registry derived for this study.
ClinicalTrials.gg
Suicide Prevention
Why
  1. Suicide is a broad heading, used only when no more specific condition is named.
  2. The study's listed conditions name Suicide Prevention, a narrower term within Suicide.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by The Hong Kong Polytechnic University · Not applicable, Interventional, and Prevention

Phase
Not applicable
Study type
Interventional
Enrollment
80
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

Suicide is a major public health concern and there is a need for accessible and scalable interventions to support individuals experiencing suicidal thoughts. The aim of this study is to develop a digital Acceptance and Commitment Therapy (ACT) intervention for suicide prevention in Chinese adults through co-design. The study will involve literature review, interviews, and co-design activities to identify user needs, preferences, and contextual factors, and to develop the intervention. Following intervention development, a pilot study will be conducted to evaluate the feasibility, usability, acceptability, and user engagement of the intervention. Findings from this study will inform further refinement of the intervention and future evaluation studies.

02

Conditions studied

  • Suicide
  • Co-design
  • Suicide Prevention

Browse trials for

03

In context

Suicide Prevention Reclassified

186 studies on the registry are indexed under Suicide Prevention; 92 are open to participants now.

This study's planned enrollment of 80 is below the median of 140 across 167 interventional studies indexed under Suicide Prevention.

Browse Suicide Prevention studies →

Lead sponsor

The Hong Kong Polytechnic University is the lead sponsor of 679 studies on the registry; 257 are open to participants now.

Compared within Suicide Prevention, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Suicide. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Aged 18 years or older;

    1. Have experienced suicidal thoughts and/or behaviors;
    2. Able to read and communicate in Chinese; Professionals

    <!-- -->

    1. Aged 18 years or older;
    2. Professionals with experience relevant to suicide prevention, Acceptance and Commitment Therapy (ACT), digital mental health, or related fields;

Exclusion criteria

  1. Unable to provide or participate in study activities;

    1. Currently experiencing acute suicide risk requiring immediate intervention;
    2. Severe cognitive impairment or active psychotic symptoms that would prevent participation.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    Digital ACT Intervention

    The Digital ACT Intervention will be co-designed with stakeholders and informed by co-design activities. The intervention aims to support adults experiencing suicidal thoughts through a digital platform.

    Behavioral: Digital ACT Intervention

Interventions

  • BehavioralDigital ACT Intervention

    A co-designed digital Acceptance and Commitment Therapy (ACT) intervention for suicide prevention

06

What researchers measure

Primary outcomes

  1. Intervention completion rate

    The intervention completion rate will be assessed as the percentage of participants who complete the digital intervention, based on intervention usage records.

    Time frame: End of the intervention (approximately 2 weeks)

  2. Retention rate

    The participant retention rate will be assessed as the percentage of participants who complete the post-intervention assessment and the follow-up assessment.

    Time frame: End of the 1-month follow-up

  3. Acceptability outcome

    Acceptability of the intervention will be assessed using participant-reported ratings and feedback regarding satisfaction and overall experience with the intervention.

    Time frame: End of the intervention (approximately 2 weeks)

  4. Usability outcome

    Usability will be assessed using the System Usability Scale (SUS), a 10-item self-report questionnaire. Total scores range from 0 to 100, with higher scores indicating better usability of the intervention.

    Time frame: End of the intervention (approximately 2 weeks)

Secondary outcomes

  1. Suicide ideation

    Suicidal ideation will be assessed using the Beck Scale for Suicide Ideation (BSSI). Each item is rated on a 3-point scale ranging from 0 to 2, with higher scores indicating greater suicidal ideation.

    Time frame: Baseline, end of the 2-week intervention, and 1-month follow-up

  2. Psychological flexibility and inflexibility

    Psychological flexibility and inflexibility will be assessed using the Multidimensional Psychological Flexibility Inventory-24 (MPFI-24). Each item is rated on a 6-point scale ranging from 1 to 6. Higher scores on the flexibility and inflexibility subscales indicate greater psychological flexibility and psychological inflexibility, respectively.

    Time frame: Baseline, end of the 2-week intervention, and 1-month follow-up

  3. Psychological Distress

    Psychological distress will be assessed using the Depression Anxiety Stress Scales (DASS). Each item is rated on a 4-point scale ranging from 0 to 3, with higher scores indicating greater psychological distress.

    Time frame: Baseline, end of the 2-week intervention, and 1-month follow-up

  4. Mental well-being

    Mental well-being will be assessed using the Mental Health Continuum-Short Form (MHC-SF). Each item is rated on a 6-point scale ranging from 0 to 5, with higher scores indicating greater mental well-being.

    Time frame: Baseline, end of the 2-week intervention, and 1-month follow-up

Other outcomes

  1. Qualitative Feedback and Design Recommendations

    Qualitative feedback related to user needs, preferences, barriers, facilitators, cultural considerations, and recommendations for intervention refinement will be identified from co-design activities and feedback sessions.

    Time frame: Through study completion, an average of 6 months

  2. Cultural Relevance

    Cultural relevance of the intervention will be assessed through participant feedback regarding the appropriateness, relevance, and cultural fit of the intervention content and delivery.

    Time frame: Through study completion, an average of 6 months

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jul 2026; primary completion for Oct 2026, 3 months later.

Of 127 non-industry interventional studies with no phase under Suicide Prevention, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 53. This study's planned 3 months is below that.

Counting every sponsor, half of 129 studies reached it within 28 months; a quarter within 12 and three quarters within 53.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 9, 2026
First posted
Jul 29, 2026
StartEst.
Jul 15, 2026
Primary completionEst.
Oct 31, 2026
CompletionEst.
Dec 30, 2026
Last update
Jul 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07733596
Responsible party
Sponsor
First posted
Jul 29, 2026
Start date
Jul 15, 2026 (estimated)
Primary completion
Oct 31, 2026 (estimated)
Completion
Dec 30, 2026 (estimated)
Last update
Jul 29, 2026

Study contacts

Tao Zhang
Contact
tao-t.zhang@connect.polyu.hk
+85294233827
Tao Zhang
principal investigator · The Hong Kong Polytechnic University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion